BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19850156)

  • 1. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis.
    Sikkema M; de Jonge PJ; Steyerberg EW; Kuipers EJ
    Clin Gastroenterol Hepatol; 2010 Mar; 8(3):235-44; quiz e32. PubMed ID: 19850156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
    Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
    Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis.
    Codipilly DC; Chandar AK; Singh S; Wani S; Shaheen NJ; Inadomi JM; Chak A; Iyer PG
    Gastroenterology; 2018 Jun; 154(8):2068-2086.e5. PubMed ID: 29458154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.
    Anaparthy R; Gaddam S; Kanakadandi V; Alsop BR; Gupta N; Higbee AD; Wani SB; Singh M; Rastogi A; Bansal A; Cash BD; Young PE; Lieberman DA; Falk GW; Vargo JJ; Thota P; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1430-6. PubMed ID: 23707463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
    Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
    Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
    Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.
    Singh S; Manickam P; Amin AV; Samala N; Schouten LJ; Iyer PG; Desai TK
    Gastrointest Endosc; 2014 Jun; 79(6):897-909.e4; quiz 983.e1, 983.e3. PubMed ID: 24556051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients With Barrett's Esophagus and Persistent Low-grade Dysplasia Have an Increased Risk for High-grade Dysplasia and Cancer.
    Kestens C; Offerhaus GJ; van Baal JW; Siersema PD
    Clin Gastroenterol Hepatol; 2016 Jul; 14(7):956-962.e1. PubMed ID: 26748222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Barrett's esophagus surveillance on the prognosis of esophageal adenocarcinoma: A meta-analysis.
    Ding YE; Li Y; He XK; Sun LM
    J Dig Dis; 2018 Dec; 19(12):737-744. PubMed ID: 30375167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis.
    Yousef F; Cardwell C; Cantwell MM; Galway K; Johnston BT; Murray L
    Am J Epidemiol; 2008 Aug; 168(3):237-49. PubMed ID: 18550563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus.
    Nguyen T; Thrift AP; Yu X; Duan Z; El-Serag HB
    Am J Gastroenterol; 2017 Jul; 112(7):1049-1055. PubMed ID: 28244499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study.
    Verbeek RE; Leenders M; Ten Kate FJ; van Hillegersberg R; Vleggaar FP; van Baal JW; van Oijen MG; Siersema PD
    Am J Gastroenterol; 2014 Aug; 109(8):1215-22. PubMed ID: 24980881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
    Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
    Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus: a systematic review and meta-analysis.
    Chandrasekar VT; Hamade N; Desai M; Rai T; Gorrepati VS; Jegadeesan R; Sathyamurthy A; Sharma P
    Endoscopy; 2019 Jul; 51(7):665-672. PubMed ID: 30939618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.
    Wolf WA; Pasricha S; Cotton C; Li N; Triadafilopoulos G; Muthusamy VR; Chmielewski GW; Corbett FS; Camara DS; Lightdale CJ; Wolfsen H; Chang KJ; Overholt BF; Pruitt RE; Ertan A; Komanduri S; Infantolino A; Rothstein RI; Shaheen NJ
    Gastroenterology; 2015 Dec; 149(7):1752-1761.e1. PubMed ID: 26327132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy.
    Peters Y; Honing J; Kievit W; Kestens C; Pestman W; Nagtegaal ID; van der Post RS; Siersema PD
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):869-877.e5. PubMed ID: 30213587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.
    Thota PN; Kistangari G; Singh P; Cummings L; Hajifathalian K; Lopez R; Sanaka MR
    Dig Dis Sci; 2016 Jan; 61(1):247-54. PubMed ID: 26233550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.
    Sikkema M; Looman CW; Steyerberg EW; Kerkhof M; Kastelein F; van Dekken H; van Vuuren AJ; Bode WA; van der Valk H; Ouwendijk RJ; Giard R; Lesterhuis W; Heinhuis R; Klinkenberg EC; Meijer GA; ter Borg F; Arends JW; Kolkman JJ; van Baarlen J; de Vries RA; Mulder AH; van Tilburg AJ; Offerhaus GJ; ten Kate FJ; Kusters JG; Kuipers EJ; Siersema PD
    Am J Gastroenterol; 2011 Jul; 106(7):1231-8. PubMed ID: 21577245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.